Amoy Diagnostics (SHE:300685) secured regulatory approval from China's medical products administrator for the expanded use of its cancer gene detection kit.

The Human 10-Gene Mutation detection kit can now detect EGFR exon 20 insertion mutations in plasma samples from non-small cell lung cancer patients, according to a Monday filing with the Shenzhen bourse.

Shares of the diagnostics company closed 1% higher Tuesday.